Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07780019 | Microwave Ablation of Uterine Fibroids(MyoMwa) | active not recruiting | — | 100 | Turku University HospitalOTHER_GOV | 1 | Aug 21, 2026 | clinicaltrials |
| NCT00977457 | Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery | active not recruiting | Phase 1 | 1,045 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 |
| clinicaltrials |
| NCT03355976 | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | active not recruiting | Phase 2 | 46 | Brown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04457232 | Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation(FAPI PET Prost) | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04557449 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors(CDK4i) | active not recruiting | Phase 2 | 362 | PfizerINDUSTRY | 8 | Aug 20, 2026 | clinicaltrials |
| NCT04569773 | Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer | active not recruiting | — | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04596384 | Home Base Telemonitoring in Gastrointestinal, Genitourinary, or Gynecologic Cancer Patients Undergoing Abdominal Surgery | active not recruiting | N/A | 398 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04673448 | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05364008 | FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea(FRIEND) | active not recruiting | Phase 3 | 33 | Yale UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06995053 | Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial(ILLUSION) | active not recruiting | N/A | 91 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07777094 | TS Triage of HR-HPV Positive Population and Its Accuracy Study | active not recruiting | — | 300 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04506567 | Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC | active not recruiting | Phase 1 | 60 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04550494 | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04819997 | A Nurse-Led Intervention for Fear of Progression in Advanced Cancer | active not recruiting | N/A | 42 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05424783 | MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)(MAGIC) | active not recruiting | — | 222 | Northwestern UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06402383 | Supporting the National Expansion of HPV-based Cervical Cancer Screening in Tanzania Among Women Living With HIV | active not recruiting | N/A | 2,000 | Dr. Karen YeatesOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03732820 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 3 | 895 | AstraZenecaINDUSTRY | 17 | Aug 18, 2026 | clinicaltrials |
| NCT05471128 | MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy(OU-SCC-PROBX) | active not recruiting | — | 29 | University of OklahomaOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06943833 | A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)(IVOLGA) | active not recruiting | Phase 2 | 37 | AstraZenecaINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT01407263 | Trial of Modifications to Radical Prostatectomy | active not recruiting | Phase 3 | 3,204 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04134260 | Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | active not recruiting | Phase 3 | 586 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT04513717 | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial | active not recruiting | Phase 3 | 2,753 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05053152 | Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study | active not recruiting | Phase 2 | 194 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05415709 | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer | active not recruiting | Early Phase 1 | 35 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06235151 | Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer(Solar-Stage) | active not recruiting | Phase 3 | 439 | Curium US LLCINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07766486 | Prospective Study on the Role of Radical Prostatectomy in Oligo-metastatic Hormone-sensitive Prostate Cancer in Patients on Androgen Deprivation Therapy(MAZINGA) | active not recruiting | N/A | 30 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT00514254 | Risk Factors for Endometrial Cancer in Black Women | active not recruiting | — | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03624660 | Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer(PR11) | active not recruiting | Phase 2 | 100 | University of FloridaOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05350475 | Protons vs. Photons for High-risk Prostate Cancer | active not recruiting | N/A | 102 | University of AarhusOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05722288 | Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers | active not recruiting | Phase 2 | 49 | City of Hope Medical CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT01688492 | Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT01737242 | UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies(UKGPCS) | active not recruiting | — | 23,826 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03943173 | Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | active not recruiting | Early Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04007770 | Acupuncture Pilot Study for Cancer-related Cognitive Function | active not recruiting | Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04126070 | Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors | active not recruiting | Phase 2 | 47 | Xiao X. Wei, MDOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05063916 | Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05601752 | ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) | active not recruiting | Phase 2 | 66 | USWM CT, LLCINDUSTRY | 5 | Aug 12, 2026 | clinicaltrials |
| NCT01786265 | Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | active not recruiting | Phase 2 | 310 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT02884648 | Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery | active not recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03575832 | Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners | active not recruiting | N/A | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06792435 | XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | active not recruiting | Phase 1 / Phase 2 | 240 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT02949284 | Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery | active not recruiting | Phase 2 | 90 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05114421 | Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03706365 | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer(CYCLONE 2) | active not recruiting | Phase 2 / Phase 3 | 393 | Eli Lilly and CompanyINDUSTRY | 11 | Aug 7, 2026 | clinicaltrials |
| NCT05513443 | Prostate Cancer IRE Study (PRIS)(PRIS) | active not recruiting | N/A | 184 | Karolinska InstitutetOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05673252 | CERvical Cancer The InFlammatory Index (CERTIFIKO)(CERTIFIKO) | active not recruiting | — | 128 | University of Campania Luigi VanvitelliOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06305598 | Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Aug 7, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 21, 2026source: clinicaltrials